MBX Biosciences (MBX) News Today $12.15 -0.36 (-2.88%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$12.15 0.00 (0.00%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MBX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Woodline Partners LP Buys 89,046 Shares of MBX Biosciences, Inc. (NYSE:MBX)Woodline Partners LP lifted its position in MBX Biosciences, Inc. (NYSE:MBX - Free Report) by 17.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 608,721 shares of the company's sMay 25 at 4:41 AM | marketbeat.comCitadel Advisors LLC Grows Stock Holdings in MBX Biosciences, Inc. (NYSE:MBX)Citadel Advisors LLC lifted its stake in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) by 62.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 220,330 shares of the company's stock after purchasMay 21, 2025 | marketbeat.comMBX Biosciences to Participate in June Investor ConferencesMay 20, 2025 | globenewswire.comParkman Healthcare Partners LLC Purchases New Shares in MBX Biosciences, Inc. (NYSE:MBX)Parkman Healthcare Partners LLC purchased a new position in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 170,000 shares of the company's stock, valued atMay 16, 2025 | marketbeat.comMBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsMay 12, 2025 | globenewswire.comDriehaus Capital Management LLC Acquires 600,438 Shares of MBX Biosciences, Inc. (NYSE:MBX)Driehaus Capital Management LLC increased its holdings in MBX Biosciences, Inc. (NYSE:MBX - Free Report) by 61.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,581,760 shares of the company's stocMay 11, 2025 | marketbeat.comFESM's Underlying Holdings Could Mean 34% Gain PotentialMay 10, 2025 | nasdaq.comMBX Biosciences, Inc. (NYSE:MBX) Stake Lessened by Alyeska Investment Group L.P.Alyeska Investment Group L.P. decreased its position in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) by 22.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 174,700May 9, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Purchases New Position in MBX Biosciences, Inc. (NYSE:MBX)Schonfeld Strategic Advisors LLC acquired a new position in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 71,500 shares of the company's stock, valued at approMay 9, 2025 | marketbeat.comMBX Biosciences, Inc. (NYSE:MBX) Receives Consensus Rating of "Buy" from AnalystsShares of MBX Biosciences, Inc. (NYSE:MBX - Get Free Report) have earned a consensus recommendation of "Buy" from the six analysts that are covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 12-month price target among brokersMay 6, 2025 | marketbeat.comMBX Biosciences, Inc. (NYSE:MBX) Shares Sold by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD trimmed its holdings in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) by 2.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,161,527 shares of the company's stock after selling 31,411 shares during thMay 4, 2025 | marketbeat.comMBX Biosciences, Inc. (NYSE:MBX) Shares Purchased by Geode Capital Management LLCGeode Capital Management LLC grew its position in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) by 1,093.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 265,703 shares of the company's stock after purchasingApril 28, 2025 | marketbeat.comCompanies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In GrowthApril 23, 2025 | finance.yahoo.comMBX Biosciences to Participate in Citizens and RBC May Investor ConferencesApril 22, 2025 | globenewswire.comAscendis Pharma initiated with an Outperform at RBC CapitalApril 16, 2025 | markets.businessinsider.comFranklin Resources Inc. Cuts Stock Holdings in MBX Biosciences, Inc. (NYSE:MBX)Franklin Resources Inc. decreased its position in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) by 17.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 369,300 shares of the company's stock aApril 12, 2025 | marketbeat.comJMP Securities Initiates Coverage of MBX Biosciences (MBX) with Market Outperform RecommendationApril 11, 2025 | msn.comOra H. Pescovitz Buys 7,693 Shares of MBX Biosciences, Inc. (NYSE:MBX) StockApril 11, 2025 | insidertrades.comMBX Biosciences initiated with an Outperform at Citizens JMPApril 10, 2025 | markets.businessinsider.comMBX Biosciences adds biotech veteran to boardApril 9, 2025 | uk.investing.comMBX Biosciences appoints Steve Hoerter to board of directorsApril 8, 2025 | markets.businessinsider.comMBX Biosciences Appoints Steve Hoerter to BoardApril 7, 2025 | tipranks.comCharles Schwab Investment Management Inc. Invests $1.72 Million in MBX Biosciences, Inc. (NYSE:MBX)Charles Schwab Investment Management Inc. bought a new stake in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 93,311 shares of the company'sMarch 30, 2025 | marketbeat.comMBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 26, 2025 | globenewswire.comMBX Biosciences reports Q4 EPS (47c), consensus (59c)March 17, 2025 | markets.businessinsider.comMBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate HighlightsMarch 17, 2025 | globenewswire.comInsider Buyers At MBX Biosciences Likely Disappointed With 17% SlideMarch 13, 2025 | finance.yahoo.comMBX Biosciences announces additions to its leadership teamMarch 6, 2025 | markets.businessinsider.comMBX Biosciences Announces Additions to Leadership TeamMarch 5, 2025 | globenewswire.comMBX Biosciences, Inc.'s Lock-Up Period Will Expire on March 12th (NYSE:MBX)MBX Biosciences' (NYSE:MBX - Get Free Report) lock-up period is set to expire on Wednesday, March 12th. MBX Biosciences had issued 10,200,000 shares in its initial public offering on September 13th. The total size of the offering was $163,200,000 based on an initial share price of $16.00. After the expiration of MBX Biosciences' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.March 5, 2025 | marketbeat.comMBX Biosciences completes enrollment in Phase 2 Avail trial of MBX 2109March 3, 2025 | markets.businessinsider.comMBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for HypoparathyroidismMarch 3, 2025 | globenewswire.comOrbiMed Advisors makes $2 million investment in MBX BiosciencesFebruary 22, 2025 | investing.comMbx biosciences director Carl Gordon purchases over $2 million in stockFebruary 22, 2025 | investing.comInsider Buying: MBX Biosciences, Inc. (NYSE:MBX) Director Acquires 47,502 Shares of StockMBX Biosciences, Inc. (NYSE:MBX - Get Free Report) Director Carl L. Gordon purchased 47,502 shares of the firm's stock in a transaction on Friday, February 14th. The stock was acquired at an average price of $9.87 per share, with a total value of $468,844.74. Following the completion of the transaction, the director now owns 3,205,930 shares in the company, valued at approximately $31,642,529.10. This trade represents a 1.50 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.February 20, 2025 | marketbeat.comMBX Biosciences, Inc. (NYSE:MBX) Director Carl L. Gordon Purchases 143,170 SharesMBX Biosciences, Inc. (NYSE:MBX - Get Free Report) Director Carl L. Gordon acquired 143,170 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was acquired at an average cost of $10.84 per share, for a total transaction of $1,551,962.80. Following the transaction, the director now directly owns 3,255,000 shares in the company, valued at $35,284,200. The trade was a 4.60 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.February 20, 2025 | marketbeat.comInsider Buying: MBX Biosciences, Inc. (NYSE:MBX) Director Buys 47,502 Shares of StockMBX Biosciences, Inc. (NYSE:MBX - Get Free Report) Director Carl L. Gordon purchased 47,502 shares of the stock in a transaction dated Friday, February 14th. The shares were acquired at an average price of $9.87 per share, with a total value of $468,844.74. Following the transaction, the director now owns 3,205,930 shares in the company, valued at $31,642,529.10. This trade represents a 1.50 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.February 20, 2025 | marketbeat.comMBX Biosciences to Participate in March Investor ConferencesFebruary 18, 2025 | globenewswire.comSmaller biotechs see new mechanisms of actions as future of obesity treatmentsFebruary 10, 2025 | msn.comStifel Nicolaus Reaffirms Their Buy Rating on MBX Biosciences, Inc. (MBX)February 10, 2025 | markets.businessinsider.comP. Kent Hawryluk Acquires 50,000 Shares of MBX Biosciences, Inc. (NYSE:MBX) StockMBX Biosciences, Inc. (NYSE:MBX - Get Free Report) CEO P. Kent Hawryluk acquired 50,000 shares of the company's stock in a transaction dated Tuesday, February 4th. The stock was acquired at an average cost of $10.69 per share, for a total transaction of $534,500.00. Following the completion of the purchase, the chief executive officer now directly owns 448,277 shares in the company, valued at $4,792,081.13. This trade represents a 12.55 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.February 5, 2025 | marketbeat.comMaze Therapeutics valued at $690.4 million in lukewarm Nasdaq debutJanuary 31, 2025 | msn.comMetsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debutJanuary 31, 2025 | msn.comWeight-loss drug developer Metsera raises $275 million in US IPOJanuary 31, 2025 | msn.comWeight-loss drug developer Metsera seeks up to $1.78 billion valuation in US IPOJanuary 27, 2025 | msn.comWeight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPOJanuary 27, 2025 | msn.comMBX Biosciences to Participate in Upcoming February Investor ConferencesJanuary 23, 2025 | finance.yahoo.comWeight-loss drug developer Metsera reveals wider loss in US IPO filingJanuary 11, 2025 | msn.comEarly success for MBX in Phase I trial of GLP-1RA for hypoglycaemiaJanuary 8, 2025 | msn.comMBX Biosciences announces phase 1 topline resuts for MBX 1416January 8, 2025 | markets.businessinsider.com Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Email Address MBX Media Mentions By Week MBX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MBX News Sentiment▼1.110.77▲Average Medical News Sentiment MBX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MBX Articles This Week▼32▲MBX Articles Average Week Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Indivior News Today Biohaven News Today IDEAYA Biosciences News Today Edgewise Therapeutics News Today Immunocore News Today Travere Therapeutics News Today Mesoblast News Today Structure Therapeutics News Today Janux Therapeutics News Today Evotec News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:MBX) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MBX Stock Free MBX Stock Alerts